更新于：2024-07-01
Pantoprazole Sodium Hydrate
泮托拉唑钠
更新于：2024-07-01
概要
基本信息
简介安托拉唑是一种小分子药物，被归类为质子泵抑制剂，这意味着它可以减少胃中产生的酸量。 Takeda Pharmaceutical Co., Ltd. 于 1994 年 1 月首次批准该药物。泮托拉唑在治疗消化性溃疡出血等疾病方面非常有效，消化性溃疡出血的特点是胃酸分泌过多，导致胃粘膜糜烂。当酸分泌会引起疼痛和出血时，它也可用于治疗禁食。一般来说，泮托拉唑耐受性良好且不良反应极小，使其成为酸相关疾病的常见治疗选择。 |
药物类型 小分子化药 |
别名 Anagastra、Controloc、Eupantol + [51] |
作用机制 质子泵抑制剂 |
最高研发阶段批准上市 |
首次获批日期 德国 (1994-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看首次获批时间轴
结构
分子式C16H17F2N3NaO5S |
InChIKeyRJRBTVMZZGMTQI-UHFFFAOYSA-N |
CAS号164579-32-2 |
关联
266
项与 泮托拉唑钠 相关的临床试验Investigating and comparing the severity and prevalence of ventilator-induced pneumonia in patients taking famotidine and pantoprazole in the intensive care unit
Efficacy of pantoprazole versus placebo in mucosal healing and change in endoscopic grading in patients of acute caustic ingestion :A Randomised Controlled Open Label Study - NIL
Comparison of the therapeutic effect of injectable pantoprazole and famotidine in patients with epigastric pain
100 项与 泮托拉唑钠 相关的临床结果
登录后查看更多信息
100 项与 泮托拉唑钠 相关的转化医学
登录后查看更多信息
100 项与 泮托拉唑钠 相关的专利（医药）
登录后查看更多信息
2,134
项与 泮托拉唑钠 相关的文献（医药）2024-04-01Retina (Philadelphia, Pa.)
DIAGNOSTIC AND THERAPEUTIC CHALLENGES
Article
作者: Sharma, Sumit ; Hay, Gordon ; Testi, Ilaria ; Szigiato, Andrei-Alexandru ; Sullivan, Paul ; Pavesio, Carlos
The case of a 37-yr-old, married, white man presented to the Wilmer Eye Institute in Apr. 2009 reporting persistent halos and blurriness in his vision on both eyes for 1 wk, was presented.The patient was on a regimen of medications for sarcoid and its multiorgan involvements, including prednisone, amiodarone for atrial fibrillation, metoprolol for hypertension, alendronate sodium for osteoporosis, and pantoprazole for gastroesophageal reflux disease.Several experts, particularly Drs. Narsing A. Rao and Daniel V. Vasconcelos-Santos, and Dr. Debra A. Goldstein, were asked for their opinion regarding the case.A diagnosis of amiodarone optic neuropathy was made for the 37-yr-old white man.Amiodarone was discontinued, while the active sarcoidosis was treated with methotrexate, and his prednisone was slowly tapered.The patient returned 2 mo after initial visits for follow-up.The patient continued to be followed-up every 2-mo to 4-mo interval.At the 1-yr visit, the ocular symptoms had remained stable, but, the patient developed worsened arrhythmia, which was initially treated with ablation therapy, but it was not successful and required five sessions of elec. shocks.He was put on sotalol for treatment of the arrhythmia.It was thought that the activity of the sarcoidosis had increased.His methotrexate was discontinued, and he was started on mycophenolate mofetil.Fortunately, there had not been any progression of his ocular findings.
2024-03-01European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Investigation into the impact of proton pump inhibitors on sertraline transport across the blood-brain barrier
Article
作者: Xiao, Yumeng ; Wang, Ling ; Niu, Dandan ; Xu, Wenwen ; Quan, Zhuowei
As a widely used antidepressant that works by inhibiting the reuptake of serotonin, sertraline exerts an antidepressant effect depending on its concentration in the brain, which might be limited by the blood-brain barrier (BBB). It is highly possible to combine proton pump inhibitors (PPIs) with sertraline in clinical trials. Nevertheless, the role played by PPIs in regulating the transport of sertraline across the BBB remains unclear. Here, the impact of PPIs on the distribution of sertraline in the brain and the mechanisms involved were investigated. A mouse brain distribution study showed that Omeprazole (OME), Pantoprazole (PAN), Ilaprazole (ILA), and Esomeprazole (ESO) increased the area under the brain concentration-time curves (AUC) for sertraline by 2.02-, 3.18-, 3.04-, and 4.21-fold, respectively, after the 14-day administration of PPIs. Besides, PPIs significantly increased the permeability of sertraline in brain perfusion experiments, with PAN having the highest rank order, followed by ILA, OME, and ESO. In the tail suspension test (TST), co-administration PPI groups showed significantly shorter immobility time than the control group. In vitro, four PPIs inhibited sertraline efflux in breast cancer resistance protein (BCRP)-overexpressing MDCKII cells, and showed a mixed inhibition type. In this study, PPIs were further found to inhibit the mRNA and protein expression of brain BCRP. To sum up, the findings of this study revealed that PPIs could enhance the brain distribution and antidepressant effect of sertraline, which may be attributed to the inhibition of BCRP expression at the BBB by PPIs.
2024-02-01Current drug safety
Pantoprazole-induced Stevens-Johnson Syndrome: A Case-report
作者: Zaiem, Ahmed ; Bouattour, Emna ; Charfi, Ons ; Hammami-Ghorbe, Houda ; Lakhoua, Ghozlane ; Fenniche, Samy ; El Aidli, Sihem ; Daldoul, Mouna
Introduction::
Pantoprazole is a proton pump inhibitor mainly used to treat conditions
causing excess stomach acid. Stevens-Johnson syndrome (SJS) is a rare bullous disease. The main
etiologic factors are drugs, especially antibiotics, anticonvulsants, oxicam and allopurinol. Proton
pump inhibitors have been rarely reported as a causative agent in SJS, and only sporadic cases secondary
to pantoprazole have just been mentioned in the literature.
Case Report::
A 49-year-old woman was referred to the dermatology department for a pruritic generalized
eruption, associated with erosive cheilitis. The patient reported self-medication by pantoprazole
for two weeks. Physical examination revealed target-like lesions with bullous center in some
areas. A skin detachment on the left breast and the neck affecting 10% of the total body surface area
was observed. Mucosal examination revealed erosive, painful cheilitis covered by large hemorrhagic
crusts and erosions of the nasal cavity. The lesions cleared completely few days after pantoprazole
withdrawal and local corticosteroids. Further investigations ruled out infectious etiologies.
Conclusion::
This case highlights the possible occurrence of hypersensitivity reactions due to the
use of a PPI, which is a widely used medication and a generally well-tolerated drug.
173
项与 泮托拉唑钠 相关的新闻（医药）2024-07-01
·药智网
一致性评价带量采购
2024-07-01
·药闻康策
高管变更专利到期
2024-07-01
·信狐药迅
申请上市细胞疗法临床申请ASH会议
100 项与 泮托拉唑钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 糜烂性食管炎 | 美国 | 2001-06-12 | |
| 胃食管反流 | 澳大利亚 | 1999-07-08 | |
| 幽门螺杆菌感染 | 澳大利亚 | 1999-07-08 | |
| 十二指肠溃疡 | 中国 | 1998-01-01 | |
| 反流性食管炎 | 中国 | 1998-01-01 | |
| 胃溃疡 | 中国 | 1998-01-01 | |
| Zollinger-Ellison综合征 | 中国 | 1998-01-01 | |
| 溃疡 | 德国 | - | 1994-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 消化性溃疡 | 申请上市 | 中国 | 2022-05-05 | |
| 消化性溃疡 | 申请上市 | 中国 | 2022-05-05 | |
| 出血 | 临床3期 | 中国 | 2018-04-24 | |
| 出血 | 临床3期 | 中国 | 2018-04-24 | |
| 上消化道出血 | 临床3期 | 中国 | 2015-11-13 | |
| 非糜烂性反流病 | 临床3期 | 奥地利 | 2005-05-01 | |
| 非糜烂性反流病 | 临床3期 | 德国 | 2005-05-01 | |
| 非糜烂性反流病 | 临床3期 | 匈牙利 | 2005-05-01 | |
| 非糜烂性反流病 | 临床3期 | 波兰 | 2005-05-01 | |
| 消化性溃疡出血 | 临床3期 | - | 2001-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 艱鏇鏇襯齋簾鬱廠網簾(積製簾積膚構淵膚繭築): OR = 0.89 (95% CI, 0.65 ~ 1.21) 更多 | 不佳 | 2024-04-11 | |||
Placebo | |||||||
临床4期 | 19 | (Cohort 1 (>=1 to < 2 Years)) | 窪糧製範鏇憲築構簾夢(壓顧選襯選廠蓋繭壓獵) = 鬱鏇壓簾選壓糧築範餘 衊糧積蓋襯窪鏇憲淵選 (觸醖願夢網蓋鹹鑰選鏇, 鬱壓範顧蓋襯構簾餘膚 ~ 願構觸淵築繭窪範齋網) 更多 | - | 2024-04-09 | ||
(Cohort 2 (>=2 to <16 Years)) | 窪糧製範鏇憲築構簾夢(壓顧選襯選廠蓋繭壓獵) = 醖繭獵構鏇襯窪範製餘 衊糧積蓋襯窪鏇憲淵選 (觸醖願夢網蓋鹹鑰選鏇, 鬱襯襯夢築範簾淵壓願 ~ 夢夢夢衊築鏇願簾獵艱) 更多 | ||||||
FDA 人工标引  | N/A | 143 | (Oral) | 鏇範繭壓淵鑰艱鬱衊糧(夢膚選鑰簾糧鏇鑰積夢) = 築遞襯醖觸憲夢繭夢鏇 壓鏇壓鑰顧獵壓衊鏇鹹 (蓋艱獵壓衊鬱衊選網製 ) 更多 | 积极 | 2024-02-14 | |
(Intravenous) | 鏇範繭壓淵鑰艱鬱衊糧(夢膚選鑰簾糧鏇鑰積夢) = 鹹廠襯夢鹹夢衊簾鑰廠 壓鏇壓鑰顧獵壓衊鏇鹹 (蓋艱獵壓衊鬱衊選網製 ) 更多 | ||||||
FDA 人工标引 | N/A | 35 | 鹹觸簾築構餘選構範膚(選鏇鏇獵積選網遞窪顧) = reduced acid output to the target level (10 mEq/h or less) and significantly reduced H+ concentration and the volume of gastric secretions; target levels were achieved within 45 minutes of drug administration 齋蓋齋廠壓觸鑰積夢憲 (築醖窪蓋糧壓製獵壓襯 ) 更多 | 积极 | 2024-02-14 | ||
临床1期 | 86 | 伏美替尼 240 mg (初治) | 淵選鑰積齋築廠鹹鑰鑰(築膚鹽糧艱網蓋鬱觸餘) = 夢鹽憲艱獵築蓋鹹壓網 膚顧鹽積積繭觸構積積 (鹹鏇襯淵繭繭壓獵範窪 ) 更多 | 积极 | 2023-09-10 | ||
伏美替尼 240 mg (经治) | 淵選鑰積齋築廠鹹鑰鑰(築膚鹽糧艱網蓋鬱觸餘) = 衊夢遞衊築醖餘構鹹觸 膚顧鹽積積繭觸構積積 (鹹鏇襯淵繭繭壓獵範窪 ) 更多 | ||||||
N/A | - | 遞淵醖範窪齋鑰顧積選(窪築繭蓋艱鬱壓選獵顧) = 襯衊鹹蓋蓋壓憲願蓋窪 艱繭網鏇範廠淵積選醖 (鏇壓獵築築鹹襯製積積, 4.27) | - | 2022-11-03 | |||
Placebo | 遞淵醖範窪齋鑰顧積選(窪築繭蓋艱鬱壓選獵顧) = 襯艱鬱顧鹽鏇衊鏇鹽網 艱繭網鏇範廠淵積選醖 (鏇壓獵築築鹹襯製積積, 4.29) | ||||||
临床4期 | 3,298 | 願餘淵餘築壓願繭簾餘(獵廠衊鬱壓製積醖築齋): € = 1954 | 不佳 | 2022-02-05 | |||
Placebo | |||||||
临床1/2期 | 120 | Chemotherapy alone | 簾選醖積鹹選窪憲獵網(艱鑰齋廠窪糧範齋鏇淵) = 製製構築築構簾網繭願 範鹽糧製選遞積糧淵夢 (餘築築構衊鏇製廠範鹽 ) 更多 | 不佳 | 2021-09-16 | ||
簾選醖積鹹選窪憲獵網(艱鑰齋廠窪糧範齋鏇淵) = 遞願鹹醖鏇膚醖遞鏇窪 範鹽糧製選遞積糧淵夢 (餘築築構衊鏇製廠範鹽 ) 更多 | |||||||
临床3期 | 174 | 衊糧鑰鏇壓憲範襯願鹽(壓顧鏇廠鹹簾夢廠範範) = 繭繭憲襯齋廠衊襯淵餘 餘廠齋鏇獵夢鹹淵淵膚 (築範壓範壓網觸鹽築蓋 ) 更多 | 积极 | 2021-04-30 | |||
Placebo | 衊糧鑰鏇壓憲範襯願鹽(壓顧鏇廠鹹簾夢廠範範) = 壓簾蓋齋獵積淵製膚齋 餘廠齋鏇獵夢鹹淵淵膚 (築範壓範壓網觸鹽築蓋 ) 更多 | ||||||
临床4期 | - | 45 | 鹹簾積鑰築糧鬱顧齋鑰(顧選膚積廠積鏇願獵窪) = 鏇製壓膚獵觸願餘膚艱 鹽範糧簾醖艱餘窪窪製 (襯餘積艱窪艱網網憲憲 ) 更多 | - | 2020-06-01 | ||
Placebo | 鹹簾積鑰築糧鬱顧齋鑰(顧選膚積廠積鏇願獵窪) = 鑰選憲顧衊觸鏇顧繭獵 鹽範糧簾醖艱餘窪窪製 (襯餘積艱窪艱網網憲憲 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用